Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 3.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 46,504 shares of the biopharmaceutical company's stock after selling 1,650 shares during the quarter. Handelsbanken Fonder AB's holdings in Regeneron Pharmaceuticals were worth $29,494,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Pinney & Scofield Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $25,000. OFI Invest Asset Management bought a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $28,000. Rakuten Securities Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 15 shares in the last quarter. Tompkins Financial Corp bought a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at about $32,000. Finally, Curat Global LLC bought a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at about $32,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN traded up $3.24 during mid-day trading on Thursday, hitting $521.84. The stock had a trading volume of 873,171 shares, compared to its average volume of 874,701. The firm's 50 day moving average is $563.74 and its 200 day moving average is $651.53. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The stock has a market capitalization of $56.34 billion, a price-to-earnings ratio of 13.63, a PEG ratio of 2.34 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same period last year, the business earned $9.55 earnings per share. The firm's revenue was down 3.7% compared to the same quarter last year. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.67%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. UBS Group cut their target price on Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating on the stock in a research note on Thursday, June 5th. Wells Fargo & Company lowered Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and cut their target price for the company from $700.00 to $580.00 in a research note on Friday, May 30th. Royal Bank of Canada lowered Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 target price on the stock. in a research note on Friday, May 30th. Canaccord Genuity Group upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 22nd. Finally, Citigroup cut their target price on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating on the stock in a research note on Monday, June 2nd. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $836.48.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.